ML STRATEGIES, LLC for ASTELLAS PHARMA US, INC.
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
H. R. 1458, and S. 565, Comprehensive Immunosuppressive Drug coverage for Transplant Patients Act; General issues pertaining to immunosupressives.
Foreign entity interest: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JEREMY RABINOVITZ | — |
Trade (domestic/foreign) TRD
H. R. 6517, Omnibus Trade Act of 2010, miscellaneous trade provisions.
Foreign entity interest: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JEREMY RABINOVITZ | — |
Health Issues HCR
H. R. 2400, Strategies to Address Antimicrobial Resistance (STARR) Act; H. R. 6331, GAIN Act; Issues pertaining to the development of new antibiotics; H. R. 3276, American Medical Isotope Production Act; H. R. 6224, 21st Century ALERT Act; Issues pertaining to the orphan drug exemption to the 340 (B) program.
Foreign entity interest: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JEREMY RABINOVITZ | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.